Clinical trial
A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteer
NCT05232175 is registered in ClinicalTrials.gov with Alteogen, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I Study to Evaluate the Tolerance, Safety and Pharmacokinetics of ALT-BB4 in Healthy Volunteer
- Lead sponsor
- Alteogen, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 18, 2022
- Completion date
- August 24, 2022
- Enrollment
- 290 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
health, subjective